首页> 外文期刊>Journal of chromatography, B. Analytical technologies in the biomedical and life sciences >Development and validation of a dried blood spot assay for the quantification of ribavirin using liquid chromatography coupled to mass spectrometry
【24h】

Development and validation of a dried blood spot assay for the quantification of ribavirin using liquid chromatography coupled to mass spectrometry

机译:液相色谱-质谱联用技术鉴定利巴韦林的干血斑测定方法的开发和验证

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Efficient, inexpensive and sensitive assays for the measurement of drugs are of interest for pharmacokinetic and pharmacodynamics (PK-PD) analysis. Dried blood spots (DBS) are a unique bioanaltyical matrix with the potential to fulfill this interest for the measurement of numerous analytes. Here we describe the development and validation of a reversed-phase high performance liquid chromatographic (LC), tandem mass spectrometry (MS/MS) assay for the determination of ribavirin (RBV) in DBS. A 3 mm punch from spotted and dried whole blood was extracted in methanol utilizing isotopically labeled internal standard for LC-MS/MS analysis. Validation was performed over a range of 0.05 μg/mL to 10.0μg/mL and the method was shown to be precise (coefficient of variation ≤15%) and accurate (within ±15% of control). These acceptance criteria were met for hematocrit ranges of 20-54%, for center versus edge punches and for spot volumes from 10 to 60 μL. RBV was stable for up to 140 days at room temperature and -20℃ as well as for three freeze/thaw cycles. Correlation of RBV in DBS versus in plasma yielded r~2 ≥ 0.98 demonstrating that DBS can be used as an alternative to plasma for PK-PD studies in human subjects.
机译:药物动力学和药效学(PK-PD)分析对药物的测量有效,廉价和敏感。干血斑(DBS)是独特的生物镇痛药基质,有望满足测量多种分析物的兴趣。在这里,我们描述了反相高效液相色谱(LC),串联质谱(MS / MS)测定法在DBS中测定病毒唑(RBV)的开发和验证。利用同位素标记的内标进行LC-MS / MS分析,从斑点和干燥的全血中取出一个3毫米的冲头,用甲醇萃取。在0.05μg/ mL到10.0μg/ mL的范围内进行验证,结果表明该方法准确(变异系数≤15%)和准确(对照的±15%以内)。对于血细胞比容范围为20-54%,中心打孔和边缘打孔以及10至60μL的斑点量,均满足这些接受标准。 RBV在室温和-20℃以及长达三个冷冻/融化循环中可稳定长达140天。 DBS与血浆中RBV的相关性得出r〜2≥0.98,表明DBS可以用作人类受试者PK-PD研究的血浆替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号